Hedge Fund and Insider Trading News: Steve Cohen, Ken Griffin, Starboard Value, Angelo Gordon & Co., Ancora Advisors, Smartsheet Inc (SMAR), and More

Angelo Gordon’s Twin Brook Capital Partners Commits Record $3.5 Billion to Private Equity-Backed Healthcare Transactions In 2021 (BusinessWire)
NEW YORK & CHICAGO–(BUSINESS WIRE)–Twin Brook Capital Partners (“Twin Brook” or the “Firm”), the middle market direct lending subsidiary of Angelo Gordon, today announced that it committed $3.5 billion to private equity sponsors in support of healthcare transactions last year, completing 60 healthcare transactions across 33 subsectors. The Firm served as lead agent on nearly all the healthcare transactions it supported in 2021, which included 28 new platform financings and 32 add-on financings. An experienced lender in the space, Twin Brook has deployed over $6.5 billion across 169 middle market healthcare transactions since inception.

Point72 Ventures is Using its Fintech Playbook to Evaluate Potential Crypto Investments. Here’s How Steve Cohen’s Firm is ‘Building Bridges’ to Web 3.0. (Business Insider)
Billionaire Steve Cohen‘s Point72 Ventures is a growing player in the crypto space. Adam Carson leads Point72 Ventures’ crypto strategy, which has made five investments in nine months. Carson walked Insider though the firm’s process for sourcing and valuing different investments. Last year, billionaire Point72 founder Steve Cohen went to his venture capital unit and said he was ready to start investing in crypto.

Activist Hedge Fund Starboard Nominates Four Directors to Huntsman Board (Reuters)
Jan 12 (Reuters) – Activist hedge fund Starboard said on Wednesday it has nominated four directors to chemicals maker Huntsman Corp’s board at the company’s 2022 annual meeting of shareholders.

Countries with the Smallest Government Per Capita in the World

Pressmaster/Shutterstock.com

Ken Griffin’s Fortune Soars to $28 Billion on Citadel Securities Deal (Bloomberg)
Ken Griffin has for years been one of the wealthiest people on the planet thanks to his hedge fund’s success. Now it’s his powerhouse market maker that’s driving the bulk of his fortune to new heights. The billionaire sold a $1.15 billion stake in Chicago-based Citadel Securities to Sequoia Capital and Paradigm, valuing the firm at approximately $22 billion. After the outside investment, Griffin, 53, will own roughly 80% of the trading business, worth about $17.5 billion.

2022 Preqin Global Hedge Fund Report (Preqin)
The 2022 Preqin Global Hedge Fund report is the industry’s most complete and in-depth annual review. Hedge fund assets under management passed the $4tn milestone last year, reaching $4.32tn as of September. Investors rewarded the industry for its performance through turbulent markets, with an additional $41bn of inflows in Q1-Q3.

Madison Realty Capital Closes $2bn Fifth Fund (Opalesque)
Madison Realty Capital, a vertically integrated real estate private equity firm focused on bond and equity strategies, announced the final close of Madison Realty Capital Debt Fund V, raising $2.08bn in equity commitments, exceeding the fund’s $1.75bn target. Fund V received significant support from existing investors as approximately 70% of the institutional LPs in Madison’s prior fund re-upped into Fund V, said a press release from the New York-based nonbank lender that manages approximately $8 billion in total assets on behalf of a global institutional investor base.

Billionaire Hedge Fund Trader Paul Tudor Jones on the Most Important Stock Metric. It’s No Longer Profits (CNBC)
Paul Tudor Jones, the billionaire hedge fund trader who co-founded ESG investing research firm Just Capital, said companies that are motivated solely by profits can create the ability to be amoral in their decision marking. Instead, the companies that are doing the best are focusing on the “most important metrics, which are generally pocketbook issues and work-related,” Jones said.

Brevan Howard Partners Share GBP120m Pandemic Payout (Hedge Week)
Seventeen partners at hedge fund Brevan Howard have shared a bumper GBP120 million payout after profits surged following a series of successful bets during the first year of the coronavirus pandemic, according to reports in The Times and The Daily Telegraph. Founder Alan Howard took the lion’s share earning over GBP55 million in the year to end March 2021, up from GBP29.9 million in the previous twelve months.

Analysis: Elliott, Ancora Lead Hedge Funds in Pushing for More Women on Boards (Reuters)
Jan 12 (Reuters) – Elliott Management Corp and Ancora Advisors LLC led activist hedge funds in pushing for women to join corporate boards last year, as a Wall Street old boys’ network makes strides toward diversity.

Hedge Funds Rocked by Recent IPOs (Institutional Investor)
Once a source of the biggest gains for hedge funds, previously private investments that have recently gone public have plummeted below their IPO prices. More trouble in private investments… or post-private investments. A major source of gains for many hedge funds for most of 2021 has suddenly become a major source of losses. And this recent trend has accelerated amid the recent stock market selloff and increased volatility.

Insider Buying: Radiopharm Theranostics Ltd (ASX:RAD) Insider Buys 100,000 Shares of Stock (ETF Daily News)
Radiopharm Theranostics Ltd (ASX:RAD) insider Riccardo Canevari purchased 100,000 shares of Radiopharm Theranostics stock in a transaction on Friday, January 7th. The shares were acquired at an average price of A$0.37 ($0.27) per share, with a total value of A$37,000.00 ($26,618.71).

Wednesday 1/12 Insider Buying Report: SMAR, VIGL (Nasdaq.com)
At SmartSheet, a filing with the SEC revealed that on Friday, Director James N. White bought 150,000 shares of SMAR, at a cost of $63.07 each, for a total investment of $9.46M. White was up about 9.0% on the buy at the high point of today’s trading session, with SMAR trading as high as $68.76 at last check today. SmartSheet is trading up about 3.7% on the day Wednesday. And at Vigil Neuroscience, there was insider buying on Tuesday, by Director Bruce Booth who purchased 535,000 shares at a cost of $14.00 each, for a trade totaling $7.49M. This purchase marks the first one filed by Booth in the past twelve months. Vigil Neuroscience is trading up about 4.4% on the day Wednesday. Bargain hunters can buy VIGL even cheaper than Booth did, with the stock changing hands as low as $12.01 in trading on Wednesday which is 14.2% below Booth’s purchase price.